<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368339</url>
  </required_header>
  <id_info>
    <org_study_id>17-100-0007</org_study_id>
    <nct_id>NCT03368339</nct_id>
  </id_info>
  <brief_title>Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis</brief_title>
  <official_title>Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using Conjunctival Allergen Challenge Model (Ora-CAC®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Realm Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Realm Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%)
      compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
      using a modified Conjunctival Allergen Challenge Model (Ora-CAC®).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center, Double-Masked, Randomized, Phase 2 Evaluation of the Effectiveness of PR013
      Topical Ophthalmic Drops (0.045% and 0.06%) Compared to Vehicle of PR013 Topical Ophthalmic
      Drops for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen
      Challenge Model (Ora-CAC®)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular itching evaluated by the subject</measure>
    <time_frame>[Time Frame: Efficacy assessment period (Day 7 through Day 8)]</time_frame>
    <description>The method of assessment for this outcome is the Ora Calibra(TM) Conjunctival Allergen Challenge Ocular Itching Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival redness evaluated by the Investigator</measure>
    <time_frame>[Time Frame: Efficacy assessment period (Day 7 through Day 8)]</time_frame>
    <description>Ora Calibra(TM) Ocular Hyperemia Scale</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>PR013 topical Ophthalmic Drops (0.045%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PR013 topical Ophthalmic Drops (0.06%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR013 (0.045%)</intervention_name>
    <description>PR013 topical Ophthalmic Drops (0.045%)</description>
    <arm_group_label>PR013 topical Ophthalmic Drops (0.045%)</arm_group_label>
    <other_name>HOCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR013 (0.06%)</intervention_name>
    <description>PR013 topical Ophthalmic Drops (0.06%)</description>
    <arm_group_label>PR013 topical Ophthalmic Drops (0.06%)</arm_group_label>
    <other_name>HOCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be at least 10 years of age of either sex and any race

          -  have a positive history of ocular allergies and a positive skin test reaction to a
             perennial allergen (cat dander, dog dander, dust mites, cockroaches) and a seasonal
             allergen (trees, grasses, and/or ragweed) as confirmed by an allergic skin test within
             the past 24 months.

          -  have a calculated visual acuity of 0.7 logMAR or better in each eye as measured using
             an Early Treatment Diabetic Retinopathy Study (ETDRS) chart

        Exclusion Criteria:

          -  have known contraindications or sensitivities to the use of the investigational
             product or any of its components

          -  have any ocular condition that, in the opinion of the investigator, could affect the
             subject's safety or trial parameters (including but not limited to narrow angle
             glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis,
             pterygium or a diagnosis of dry eye)

          -  have had ocular surgical intervention within 3 months prior to Visit 1 or during the
             study and/or a history of refractive surgery within the past 6 months

          -  have a known history of retinal detachment, diabetic retinopathy, or active retinal
             disease

          -  have the presence of an active ocular infection (bacterial, viral or fungal) or
             positive history of an ocular herpetic infection at any visit

          -  use any of the disallowed medications* during the period indicated prior to Visit 1
             and during the study

          -  have any significant illness (e.g. any autoimmune disease requiring therapy, severe
             cardiovascular disease [including arrhythmias] the investigator feels could be
             expected to interfere with the subject's health or with the study parameters and/or
             put the subject at any unnecessary risk (includes but is not limited to: poorly
             controlled hypertension or poorly controlled diabetes, a history of status
             asthmaticus, organ transplants, a known history of persistent moderate or severe
             asthma, or a known history of moderate to severe allergic asthmatic reactions to any
             of the study allergens;

          -  have planned surgery (ocular or systemic) during the trial period or within 30 days
             after;

          -  have used an investigational drug or medical device within 30 days of the study or be
             concurrently enrolled in another investigational product trial;

          -  be a female who is currently pregnant, planning a pregnancy, or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Peters</last_name>
    <role>Study Director</role>
    <affiliation>Realm Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Crossley</last_name>
    <phone>4843212700</phone>
    <email>Valerie@realmtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Goin</last_name>
    <phone>4843212700</phone>
    <email>kgoin@realmtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Principal Investigator</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

